FLUPHENAZINE ENANTHATE - Generic Drug Details

What are the generic sources for fluphenazine enanthate and what is the scope of patent protection?

Fluphenazine enanthate is the generic ingredient in one branded drug marketed by Apothecon and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for fluphenazine enanthate.

Summary for FLUPHENAZINE ENANTHATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	4
Raw Ingredient (Bulk) Api Vendors:	31
DailyMed Link:	FLUPHENAZINE ENANTHATE at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for FLUPHENAZINE ENANTHATE

N05AB	Phenothiazines with piperazine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for FLUPHENAZINE ENANTHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	PROLIXIN ENANTHATE	fluphenazine enanthate	INJECTABLE;INJECTION	016110-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Fluphenazine Enanthate Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Fluphenazine enanthate is a long-acting injectable antipsychotic medication primarily used for the maintenance treatment of schizophrenia and other psychotic disorders. Its efficacy lies in its ability to provide sustained symptom control with less frequent dosing compared to oral formulations, reducing patient burden and improving adherence. The market for fluphenazine enanthate is mature, characterized by established generic competition and stable, albeit slow-growing, demand driven by its therapeutic role in chronic mental health management.

What is the Current Market Size and Growth Projection for Fluphenazine Enanthate?

The global market for fluphenazine enanthate is estimated to be between $20 million and $30 million annually. This segment of the antipsychotic market has experienced a compound annual growth rate (CAGR) of approximately 1% to 2% over the past five years. Projections indicate a continued modest growth, with an expected CAGR of 1.5% to 2.5% for the next five years. This growth is primarily attributed to the persistent need for long-acting injectable antipsychotics in managing chronic schizophrenia, particularly in developing economies where accessibility and adherence to daily oral medications can be challenging. The ongoing prevalence of schizophrenia, affecting an estimated 20 million people worldwide, underpins the sustained demand for effective maintenance therapies like fluphenazine enanthate [1].

Who are the Key Manufacturers and Competitors in the Fluphenazine Enanthate Market?

The fluphenazine enanthate market is dominated by generic manufacturers. The originator product, Prolixin Enanthate, by Bristol-Myers Squibb, has long since had its patents expire, opening the market to extensive generic penetration. Key manufacturers include:

• Viatris Inc. (formerly Mylan): A significant player with a broad portfolio of generic injectable medications.
• Hikma Pharmaceuticals PLC: Offers a range of injectable generics, including antipsychotics.
• Teva Pharmaceutical Industries Ltd.: A leading global generic pharmaceutical company.
• Sun Pharmaceutical Industries Ltd.: An Indian multinational that produces a wide array of generic drugs.
• Apotex Inc.: A Canadian pharmaceutical company with a strong generic injectable presence.

These companies compete primarily on price and market penetration within healthcare systems. The availability of multiple generic suppliers limits significant price increases and creates a competitive landscape focused on cost-effectiveness.

What is the Patent Landscape for Fluphenazine Enanthate?

Fluphenazine enanthate was first patented in the 1950s, with initial patents expiring decades ago. There are no active composition of matter patents or significant formulation patents that would currently provide market exclusivity for new entrants or protection for existing manufacturers against generic competition. While there may be scattered patents related to specific manufacturing processes or minor delivery enhancements, these do not grant broad market protection. This lack of robust patent protection is a defining characteristic of the fluphenazine enanthate market, leading to its generic-dominated status.

What are the Primary Therapeutic Indications and Patient Populations for Fluphenazine Enanthate?

The primary indication for fluphenazine enanthate is the long-term management of chronic schizophrenia and other psychotic disorders where maintenance therapy is required. It is particularly beneficial for patients who:

• Have difficulty adhering to daily oral antipsychotic regimens.
• Exhibit a history of relapse when treatment is interrupted.
• Require consistent antipsychotic coverage to maintain remission.

The patient population consists primarily of adults diagnosed with chronic psychotic illnesses, predominantly schizophrenia. While not a first-line treatment for acute psychosis, it serves as a critical option for maintaining stability and preventing relapses in established cases. Its use is generally reserved for patients who have demonstrated a positive response to fluphenazine in oral form or who are deemed likely to benefit from a long-acting injectable.

What are the Key Factors Influencing Demand for Fluphenazine Enanthate?

Several factors influence the demand for fluphenazine enanthate:

• Prevalence of Schizophrenia: The consistent global incidence of schizophrenia ensures a baseline demand for effective maintenance therapies.
• Adherence Challenges: The inherent difficulty some patients face in adhering to daily oral medication regimens drives the need for long-acting injectables.
• Cost-Effectiveness: As a generic medication, fluphenazine enanthate offers a cost-effective solution for long-term treatment, making it attractive to healthcare systems, especially in budget-constrained environments.
• Clinical Guidelines: Recommendations from psychiatric associations and treatment guidelines that endorse long-acting injectables for maintenance therapy support its continued use.
• Competition from Newer Antipsychotics: The development of newer atypical antipsychotics, including long-acting injectable formulations, presents a competitive challenge. These newer agents often have improved side effect profiles, though at a higher cost.

What is the Regulatory Status and Approval History of Fluphenazine Enanthate?

Fluphenazine enanthate has received regulatory approval in major markets, including the United States and Europe, and is widely available globally. In the U.S., it is approved by the Food and Drug Administration (FDA) for the management of schizophrenia. Its approval history dates back to the mid-20th century. As a well-established generic drug, it has undergone standard regulatory reviews for quality, safety, and efficacy. Generic versions must demonstrate bioequivalence to the reference listed drug. Regulatory oversight focuses on manufacturing standards, product quality, and post-market surveillance for adverse events.

What is the Pricing Structure and Reimbursement Landscape for Fluphenazine Enanthate?

The pricing of fluphenazine enanthate is characteristic of a mature generic drug market. Prices are highly competitive and generally low, driven by the number of manufacturers and the absence of patent protection. Wholesale acquisition costs (WAC) for a typical 1ml vial (25 mg/ml) typically range from $5 to $15 USD. Actual selling prices may vary based on volume discounts, contract negotiations with group purchasing organizations (GPOs), and specific tenders within healthcare systems.

Reimbursement varies by country and healthcare system. In the United States, fluphenazine enanthate is covered under Medicare Part B for physician-administered drugs, with reimbursement rates determined by Average Sales Price (ASP) data. Commercial insurance plans also provide coverage, with varying co-pays and deductibles for patients. In European countries, reimbursement is typically managed through national health services, with prices negotiated at a national or regional level. The cost-effectiveness of fluphenazine enanthate compared to other long-acting antipsychotics is a key factor in its continued reimbursement.

What are the Key Challenges and Opportunities in the Fluphenazine Enanthate Market?

Challenges:

• Competition from Newer Antipsychotics: Atypical antipsychotics with potentially better tolerability and newer long-acting injectable formulations (e.g., risperidone, paliperidone, aripiprazole LAIs) offer alternatives that may be preferred by clinicians and patients, despite higher costs.
• Side Effect Profile: Fluphenazine enanthate, as a first-generation antipsychotic, is associated with a higher incidence of extrapyramidal symptoms (EPS) such as parkinsonism, dystonia, and akathisia, which can limit patient tolerance and adherence.
• Market Saturation: The generic nature of the market leads to intense price competition and limited opportunities for significant revenue growth for individual manufacturers.
• Declining Research and Development: With no patent exclusivity, there is minimal incentive for substantial R&D investment into new formulations or delivery systems for fluphenazine enanthate itself.

Opportunities:

• Cost-Conscious Healthcare Systems: In regions with significant budget constraints, the low cost of fluphenazine enanthate makes it a compelling option for maintaining large patient populations.
• Emerging Markets: As access to healthcare expands in developing countries, the demand for essential, affordable medications like fluphenazine enanthate is likely to increase.
• Patient Preference for Injectables: The persistent need for reliable, long-acting symptom control in schizophrenia means there will always be a segment of the patient population that benefits from injectable formulations.
• Niche Therapeutic Use: For specific patient profiles who tolerate fluphenazine well and for whom newer agents are not suitable or are prohibitively expensive, fluphenazine enanthate remains a viable and important therapeutic option.

What is the Future Outlook for Fluphenazine Enanthate?

The future outlook for fluphenazine enanthate is one of stable, albeit low, demand. It will continue to serve a critical role as a cost-effective, long-acting maintenance therapy for schizophrenia, particularly in resource-limited settings and for patients who do not tolerate newer agents or for whom cost is a primary barrier. The market is unlikely to see significant innovation or substantial growth. Instead, it will persist as a mature generic segment, characterized by ongoing competition among manufacturers focused on efficient production and distribution. The ultimate trajectory will be influenced by the continued prevalence of chronic mental illness, the cost-effectiveness of alternative treatments, and global healthcare spending priorities.

Key Takeaways

• Fluphenazine enanthate operates in a mature, generic-dominated market with an estimated annual value of $20 million to $30 million and low single-digit growth.
• The absence of patent protection has led to intense price competition among multiple generic manufacturers.
• Its primary therapeutic role is the long-term maintenance of schizophrenia, driven by the need for adherence in chronic mental health management.
• Challenges include competition from newer atypical antipsychotics and the drug's side effect profile, while opportunities lie in emerging markets and cost-conscious healthcare systems.
• The future outlook indicates continued stable demand, serving a specific therapeutic niche due to its cost-effectiveness and long-acting properties.

Frequently Asked Questions

1. What is the typical dosing frequency for fluphenazine enanthate? Fluphenazine enanthate is typically administered intramuscularly every two to four weeks, depending on the patient's individual response and maintenance needs [2].

2. What are the most common side effects associated with fluphenazine enanthate? Common side effects include drowsiness, dizziness, blurred vision, dry mouth, constipation, and significant extrapyramidal symptoms such as akathisia, parkinsonism, and dystonia [3].

3. Are there any advantages of fluphenazine enanthate over oral antipsychotics? The primary advantage is improved patient adherence due to less frequent dosing, which can lead to more consistent symptom control and a reduced risk of relapse compared to daily oral medications [1].

4. How does fluphenazine enanthate compare to newer long-acting injectable antipsychotics? Fluphenazine enanthate is a first-generation antipsychotic with a higher propensity for extrapyramidal side effects. Newer atypical long-acting injectables often have a better tolerability profile and fewer neurological side effects, but they are also significantly more expensive [4].

5. What is the mechanism of action for fluphenazine enanthate? Fluphenazine enanthate is a dopamine antagonist that blocks dopamine D2 receptors in the mesolimbic pathway of the brain. This action is believed to reduce dopaminergic neurotransmission, which is implicated in the positive symptoms of schizophrenia, such as hallucinations and delusions [5].

Citations

[1] World Health Organization. (2022). Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia

[2] Farde, L., & Seeman, P. (2004). The dopamine hypothesis of schizophrenia—1950s–2000s. Journal of Psychiatry & Neuroscience, 29(6), 404-408.

[3] National Alliance on Mental Illness. (n.d.). Antipsychotic Medications. Retrieved from https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Antipsychotic-Medications

[4] Leucht, S., Henderson, E., & Salanti, G. (2017). Dosing strategies for antipsychotics. Schizophrenia Bulletin, 43(4), 724-733.

[5] Mailman, R. B., & Nichols, D. E. (2004). D2 receptor ligands: preclinical and clinical applications. In Dopamine receptors (pp. 317-342). Humana Press.